Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
52 hedge funds and large institutions have $203M invested in Inozyme Pharma in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
4% more funds holding
Funds holding: 50 → 52 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10.35% less ownership
Funds ownership: 84.25% → 73.9% (-10%)
40% less capital invested
Capital invested by funds: $337M → $203M (-$134M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$9.69M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$5M |
| 3 |
JP Morgan Chase
New York
|
+$4.92M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.3M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$34.1M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$31.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.69M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.19M |
| 5 |
Millennium Management
New York
|
-$784K |
INZY Hedge Fund Activity: Q3 2021 in Review
52 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2021, worth a combined $203M — down 40% from $337M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new INZY positions and 4 closed out — a net gain of 2 holders — while 18 added to existing stakes and 14 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $9.69M. The largest seller was RA Capital Management, exiting entirely with an estimated $34.1M sold.
- 52 institutional investors held Inozyme Pharma (INZY) as of Q3 2021, up from 50 in Q2 2021.
- Funds reported $203M of Inozyme Pharma stock for Q3 2021, down 40% quarter-over-quarter.
- 6 funds opened new Inozyme Pharma positions in Q3 2021 and 4 closed out, a net change of +2 holders.
- The largest Inozyme Pharma buyer in Q3 2021 was Suvretta Capital Management, an estimated $9.69M added.
- The largest Inozyme Pharma seller in Q3 2021 was RA Capital Management, an estimated $34.1M sold.
Based on aggregated 13F filings for Q3 2021.